Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EBITDA: 2014-2025

Historic EBITDA for vTv Therapeutics (VTVT) over the last 12 years, with Sep 2025 value amounting to -$10.7 million.

  • vTv Therapeutics' EBITDA fell 64.45% to -$10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.8 million, marking a year-over-year decrease of 24.26%. This contributed to the annual value of -$24.2 million for FY2024, which is 5.18% up from last year.
  • Latest data reveals that vTv Therapeutics reported EBITDA of -$10.7 million as of Q3 2025, which was down 38.57% from -$7.7 million recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' EBITDA registered a high of -$1.6 million during Q3 2021, and its lowest value of -$11.1 million during Q4 2021.
  • Over the past 3 years, vTv Therapeutics' median EBITDA value was -$6.5 million (recorded in 2024), while the average stood at -$6.8 million.
  • Examining YoY changes over the last 5 years, vTv Therapeutics' EBITDA showed a top increase of 43.40% in 2021 and a maximum decrease of 707.05% in 2021.
  • vTv Therapeutics' EBITDA (Quarterly) stood at -$11.1 million in 2021, then spiked by 42.90% to -$6.3 million in 2022, then increased by 25.79% to -$4.7 million in 2023, then fell by 3.93% to -$4.9 million in 2024, then plummeted by 64.45% to -$10.7 million in 2025.
  • Its last three reported values are -$10.7 million in Q3 2025, -$7.7 million for Q2 2025, and -$6.5 million during Q1 2025.